A5013478988- Malaria Research and Control
- Mosquito-borne diseases and control
- vaccines and immunoinformatics approaches
- HIV Research and Treatment
- Hepatitis B Virus Studies
- Invertebrate Immune Response Mechanisms
- Immunotherapy and Immune Responses
- graph theory and CDMA systems
- Monoclonal and Polyclonal Antibodies Research
- SARS-CoV-2 and COVID-19 Research
- Computational Drug Discovery Methods
- Poxvirus research and outbreaks
- Aquaculture disease management and microbiota
- Complement system in diseases
- Viral Infections and Immunology Research
- Bacteriophages and microbial interactions
- Viral Infections and Vectors
- Vibrio bacteria research studies
- Glycosylation and Glycoproteins Research
- Sperm and Testicular Function
- Toxoplasma gondii Research Studies
- Cardiovascular Effects of Exercise
- Mathematics and Applications
- Livestock and Poultry Management
- Coding theory and cryptography
Sanofi (United States)
2020-2021
Adobe Systems (United States)
2014
Walter Reed Army Institute of Research
1992-2008
Pfizer (United States)
1998
Kenya Medical Research Institute
1996-1998
United States Army Medical Research Directorate - Africa
1996-1998
Naval Medical Research Command
1987-1997
Uniformed Services University of the Health Sciences
1997
Johns Hopkins University
1992-1997
University of Maryland, Baltimore
1997
During 1989–1999, 11 volunteers were immunized by the bites of 1001–2927 irradiated mosquitoes harboring infectious sporozoites Plasmodium falciparum (Pf) strain NF54 or clone 3D7/NF54. Ten first challenged Pf-infected 2–9 weeks after last immunization, and all protected. A volunteer 10 immunization was not Five previously protected rechallenged 23–42 a secondary 4 Two when with heterologous Pf (7G8). In total, there protection in 24 26 challenges. These results expand published findings...
Twenty malaria-naive volunteers received a recombinant Plasmodium falciparum malaria vaccine (RTS,S) containing 19 NANP repeats and the carboxy terminus (amino acids 210-398) of circumsporozoite (CS) antigen coexpressed in yeast with hepatitis B surface antigen. Ten adjuvanted alum, 10 alum plus 3-deacylated monophosphoryl lipid A (MPL). Both formulations were well tolerated immunogenic. MPL enhanced CS antibody levels (measured by ELISA, immunofluorescence, inhibition sporozoite invasion...
This study describes the safety and immunogenicity of a liposome-based vaccine injected into human subjects. Thirty healthy adult male volunteers were immunized with liposome-encapsulated recombinant protein (R32NS181) containing epitopes from repeat region circumsporozoite Plasmodium falciparum. antigen had previously been found to be poorly immunogenic in humans when it was adsorbed Al(OH)3. In present study, R32NS181 encapsulated liposomes monophosphoryl lipid A that subsequently...
Immunization of mice with Plasmodium yoelii sporozoite surface protein 2 (PySSP2) and circumsporozoite protects completely against P. yoelii. The amino acid sequence PySSP2 suggested that the thrombospondin-related anonymous (TRAP) [Robson, K. J. H., Hall, R. S., Jennings, M. W., Harris, T. R., Marsh, K., Newbold, C. I., Tate, V. E. & Weatherall, D. (1988) Nature (London) 335, 79-82] is falciparum homolog PySSP2. We report data confirming TRAP SSP2 (PfSSP2). Murine antibodies recombinant...
In a study of recombinant proteins that might be useful in developing vaccine against malaria, synthetic peptides from the circumsporozoite (CS) protein Plasmodium falciparum were found to immunogenic for mice and rabbits. Antibody repeating region CS recognized native blocked sporozoite invasion human hepatoma cells vitro. Antibodies regions I II had no biologic activity, although antibody processed by Western blot analysis. These data support feasibility stage malaria parasite using...
As part of a study potential vaccines against malaria, the protective efficacy sporozoite subunit was determined by using Plasmodium berghei murine malaria model. Mice were immunized with recombinant DNA-produced or synthetic peptide-carrier derived from repetitive epitopes circumsporozoite gene, radiation-attenuated sporozoites. Immunization elicited humoral responses that equivalent to greater than those irradiated sporozoites, yet protection challenge induced either far less achieved...
Azithromycin prevents malaria in animal models and early clinical trials. We determined the prophylactic efficacy of three antibiotic regimens given for 10 weeks (azithromycin, 250 mg daily; azithromycin, 1,000 weekly; doxycycline, 100 daily) relative to that placebo 232 adult volunteers residing an area intense transmission. Any confirmed parasitemia during study was considered a failure. Two hundred thirteen (92%) completed study. The efficacies were as follows: daily 82.7% (95% confidence...
Volunteers immunized with gamma-irradiated Plasmodium falciparum sporozoites serve as the gold standard for protective immunity against mosquito-borne malaria transmission and provide a relevant model studying immune effector mechanisms. During 7–12-month period, we four volunteers via bites of irradiated, infected mosquitoes. Following these exposures to attentuated sporozoites, all developed antibodies measured by an immunofluorescence assay enzyme-linked immunosorbent using...
To determine the characteristics of clinical illness accompanying Plasmodium falciparum infection induced by controlled exposure to infected mosquitoes, records 118 volunteers participating in studies conducted between 1985 and 1992 were reviewed. One hundred fourteen (97%) reported at least one symptom attributable malaria, with fatigue, myalgias or arthralgias, headache, chills most commonly reported. The median duration symptoms was 3 days. Fever recorded 61% volunteers; 4 had...
Seventeen malaria-naive volunteers received a recombinant Plasmodium falciparum vaccine (RLF) containing the carboxy- and amino-terminal of circumsporozoite protein (CSP) antigen without central tetrapeptide repeats. The was formulated in liposomes with either low or high dose 3-deacylated monophosphoryl lipid A (MPL) administered alum by intramuscular injection. Both formulations were well tolerated immunogenic. MPL increased sporozoite antibody titers measured ELISA, Western blot,...
Vaccines designed to protect against malaria by inducing CD8+ cytotoxic T lymphocytes (CTL) in individuals of diverse HLA backgrounds must contain multiple conserved epitopes from various preerythrocytic-stage antigens. Plasmodium falciparum sporozoite surface protein 2 (PfSSP2) is considered an important antigen for inclusion such vaccines, because CTL the P. yoelii SSP2 mice eliminating infected hepatocytes. To develop PfSSP2 as a component we investigated presence anti-PfSSP2 two HLA-B8+...
Three volunteers were immunized by repeated exposure to the bites of Plasmodium falciparum-infected, X-irradiated mosquitoes characterize immunologic responses and duration protective immunity. A primary series immunizations had been shown previously induce sterile immunity in these against sporozoite-induced P. falciparum malaria. In current study, antibodies sporozoites circulated at high levels for least 9-12 months after administered booster from infective mosquitoes. One volunteer...
The model of protective immunity induced by immunization with irradiated plasmodia sporozoites (SPZ) has become the prototype for a promising vaccine strategy based on Ab and CTL responses directed against pre-erythrocytic stage Ags, in particular circumsporozoite protein (CSP) sporozoite surface 2 (SSP2). However, results from recently conducted studies suggest that T cell additional specificities might also be required protection. We have tested this hypothesis examining human lymphocytes...
"Safety, Immunogenicity, and Efficacy of a Malaria Sporozoite Vaccine Administered with Monophosphoryl Lipid A, Cell Wall Skeleton Mycobacteria, Squalane as Adjuvant" published on Nov 1994 by The American Society Tropical Medicine Hygiene.
CD8+ CTL specific for the Plasmodium yoelii sporozoite surface protein 2 (PySSP2) protect mice against malaria. For this reason, vaccines designed to induce P. falciparum SSP2 (PfSSP2) are under development. Optimal development of PfSSP2 as a component human malaria requires characterization HLA class I-restricted Ag. purpose, PBMC from four HLA-A2+ volunteers immunized with irradiated sporozoites were stimulated recombinant vaccinia virus expressing and 35 PfSSP2-derived 15-amino acid...
An $(m,n,k,\lambda)$-relative difference set is a lifting of $(m,k,n\lambda)$-difference set. Lam gave table cyclic relative sets with $k \leq 50$ in 1977, all which were liftings $( \frac{q^d-1}{q-1},q^{d-1},q^{d-2}(q-1))$-difference sets, the parameters complements classical Singer sets. Pott found these $n$ odd and 64$ 1995. No other nontrivial are known to ended his survey on asking whether there any others. In this paper we extend searches, apply results existence circulant weighing matrices.